%0 Journal Article
%T Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition)
%A Alessandro Brunelli
%A Alessandro Tuzi
%A Baijiang Zhang
%A Biagio Ricciuti
%A Bo Zhao
%A Changli Wang
%A Chia-Chuan Liu
%A Chinese Alliance Against Lung Cancer and AME Thoracic Surgery Collaborative Group
%A Chun Chen
%A Deruo Liu
%A Fenglei Yu
%A Ganning Jiang
%A Gaofeng Li
%A Giulio Metro
%A Guibin Qiao
%A Guoguang Shao
%A Haiquan Chen
%A Haitao Ma
%A Hecheng Li
%A Hongxu Liu
%A Hui Li
%A Jian Hu
%A Jianxing He
%A Jun Liu
%A Junke Fu
%A Kaican Cai
%A Lanjun Zhang
%A Lijie Tan
%A Lin Xu
%A Lunxu Liu
%A Matteo B. Suter
%A Matthew Evison
%A Naixin Liang
%A Nobuhiko Seki
%A Qingchen Wu
%A Qingquan Luo
%A Qun Wang
%A Qunyou Tan
%A Ren¨¦ Horsleben Petersen
%A Shanqing Li
%A Shidong Xu
%A Shinji Sasada
%A Shugeng Gao
%A Songtao Xu
%A Takhiro Izumo
%A Thoracic Surgery Branch of China International Exchange and Promotion Association for Medical and Healthcare
%A Weimin Mao
%A Wenhua Liang
%A Wenjie Jiao
%A Wentao Fang
%A William Chi-Shing Cho
%A Xiangning Fu
%A Xiaofei Li
%A Xiuyi Zhi
%A Yang Liu
%A Yue Yang
%A Yunchao Huang
%A Zhongmin Peng
%A written on behalf of National Clinical Research Center for Respiratory Disease
%J SCIE-indexed Journal
%D 2019
%R 10.21037/tlcr.2019.12.14
%X Non-small cell lung cancer (NSCLC) is the most common and fatal tumor worldwide, with 2.1 million new cases and 1.77 million deaths per year (1). With the wider application of examination approaches and the improvement of health awareness, higher proportions of surgically resectable early and mid-stage lung cancers have been detected. In overall, only 50% of patients have been cured after radical resection. In other cases, however, NSCLC is highly active and recurrence and/or metastasis can easily occur after surgery. In these patients, systemic therapy as a postoperative adjuvant therapy is required to eliminate or reduce residual micro-lesions to lower the risk of recurrence; meanwhile, the patients should be closely monitored to detect early recurrence. EGFR mutation is a major mutation type in lung cancer, and is seen in about 40% of lung cancer cases in Asia (2). Compared with wild types and other mutation types, EGFR-mutant NSCLC has its unique biological properties and drug susceptibilities, and thus requires specific diagnosis and treatment strategies. This expert consensus aims to review the current evidence and provide recommendations on key issues
%U http://tlcr.amegroups.com/article/view/34453/23762